other vaccines trust in the vaccine is important for getting the world out of the pandemic. >> meg tirrellbreaking news on astrazeneca. shares are slightly higher meg, we will hear you here on cnbc meg, take care thank you. >>> all right. back to the markets. rising rates interest rates taking center stage on wall street lately. they go up technology, not always, likely goes down. high valuation names it could be very good for one beaten up sector that is the banks and financials up 12% this year after a lost 2020 for many times. where do we go from here rbc capital markets and analyst gerard cassidy good to chat with you again. rates stabilized i don't want to make mention of 1.6. it is not 0.5. with bank deposits up and stimulus checks on the way, is it all systems do to owning bank equity >> brian, thank you. the answer is yes to that question he because the banks are positioned very well to capture the growth of the economy. you heard the federal reserve come out talking about 6% real growth as you pointed out in the opening comments, the steep eveesteepening of the yield curve you mig

dose of pfizer or moderna is 80% effective in preventing covid, 90% after a second shot cnbc's meg tirrell meg, you spoke with dr. fauci a short time ago what did he have to say? >> reporter: well, shep, on that study today from the cdc i asked him if that means just one shot of the pfizer/moderna vaccines will do? no, you still need two shots here's why >> we don't know how long that 80% is durable it may drop off a cliff in two weeks or three weeks the other thing is that even though it's 80% protective, the level of antibody that it induces is far lower than after the second dose. >> reporter: and with some of the variants evading the vaccine's protection to some degree, that cushion of antibodies is needed to ensure the vaccines still work. we also talked about folks who have already had covid and the fact that one dose of the vaccine can boost their antibody levels by 1,000 fold dr. fauci expects the cdc to consider updating guidelines about whether those folks need just one shot, although he didn't expect it to be imminent. i also asked him how long the vaccine protection is likely t

merck is teaming up with johnson & johnson with the vaccine, and meg tirrell is joining us, and meg, when is the last time that two huge competitors decided, we will work together for the good of humanity. it is a feel-good story. >> it is, brian. when you see two unique partnerships and two pharma companies coming in, it is with biotech, but it is with these two companies, and jen psaki is just talking about this at the briefing just now, and this is what she said. >> learned early on, that they were, well, not early on, but recent days and they were behind on the manufacturing capacity, and so we took steps to ensure we could capitalize on the scientific breakthrough. >> so sake psaki is saying thatn j j&j said they were behind, and they want to deliver 20 million by the end of march, so we don't have details of how much that is going to speed it up, and we should get some details from president biden, but we know that merck is going to dedicate two u.s. facilities to filling the vials and making the vaccine itself, and so it could take several months to get the facilities online,

cnbc's meg tirrell tracking all of the mixed messages for us tonight. meg, isn't the lifting of these public health measures exactly what the cdc says we cannot do >> reporter: yeah, shep. public health officials have been warning the country could be headed for a fourth wave if precautions are lifted too soon. the case declines we've been seeing nationally are leveling off. >> now is not the time to relax the critical safeguards that we know can stop the spread of could he individual 19 in our communities, not when we are so close. >> governor abbott citing texas's less than 9% positivity rate as covid cases are down 2/3 from their peak in january cdc data showed 9% of adults in texas are fully vaccinated which is just less than the national epidemiologist with continuing numbers there is room for flexibility she prefers to see a phased reopening and for the mask mandate to stay in place some local leaders sounding the alarm. covid is still widespread in their community calling the state's move a huge mistake, shep >> meg, the president announced more v

always a game-changer, meg tirrell, and she spoke with the company's ceo, and not to disspur for justhe u.s., but for the world, meg. >> thank you, brian. johnson & johnson is going to be shipping 4 million doses of the newly authorized covid vaccine to the u.s. this week, and that is the third vaccine to enter the u.s. market after pfizer and moderna. it is different characteristics in that it is one dose, and can be stored in the fridge and it is efficacy with one shot, and 85% worldwide against severe disease there. is an ongoing meeting of advisers with the cdc and seeing where it might fit in with the two. other considerations because it is one shot, and fridge stable, you can use it in other pop-up sites, and those sites without a freezer capacity, and for who might this make sense? for those who might be difficult to come back for the second dose, or those who want to be vaccinated quickly or who are is mobile, and don't want to come back. so we spoke to allan gorsky this morning about it. >> we saw the pernicious strains, and we saw 85% effectiveness rate in the severe disease

cnbc's meg tirrell now, our science and medicine correspondent. how are they going to go about this, meg? >> well, shep, the world health organization has actually formed a working group to come up with new ideas, letters of the greek alphabet, colors, these are ideas being batted around, and experts tell us there's a real concern about stigma, and associated viruss and variants with locations it can lead to backlash among groups of people like is happening now has hate crimes have spiked against people with asian descent because of the association with china we spoke with professor in south africa, who told us the country's president and health minister had a specific request when they discovered a new variant, don't name it after the country. >> that can be quite discriminatory especially because this variant, we are not even sure that it origin nated in south africa. it could easily been external introduction. >> geneticists have started giving nicknames to individual mutations found in these variants, n 501 y, associated with increased transmis

cnbc's meg tirrell covers science and medicine for us. a kind of tamiflu for covid, is that right? >> reporter: that's the hope it is among the most advanced for what could be a new group of treatments for covid, oral anti-viral drugs there were hints from a medical conference this weekend that this one as well as another from another company may offer the possibility of a simple pill for the disease. dr. fauci telling us in an interview what drugs like this have been able to do for other viral diseases. >> we need the same sort of thing that we have with hiv and that we have with hepatitis c. we need an oral drug that potently can suppress the virus. i believe strongly that we will get there. the question is how quickly we'll get there. >> reporter: and it has taken longer to develop these medicines than it did for vaccines for covid or the antibody drugs authorized for high-risk patients enrollment in trials has sometimes been slower than hoped, and experts note these drugs are complex. some that are farthest along now were originally d

significantly slows the spread of covid, among people who may not even know they're infected cnbc's meg tirrell covers science and medicine for us and broke the news to me, at least, this morning on our editorial call you sounded like a kid at christmas, meg, this morning it really is great news. >> it is, shep and you know, one of the really important things about those results is that they were from a time when the more transmissible variant of the coronavirus, called b.1.1.7 was circulating in israel and the vaccine still showed those really high levels of protection now, that variant is the most prevalent among the three of concern here in the united states and the cdc has forecast it could be the dominant strain here by the end of this month. now, we also learned from the ceo that pfizer plans to start trials of an updated version of its vaccine targeting another variant, b.1.351 first identified in south africa in a few weeks. now, dr. fauci tells us it's not clear we will need booster shots of the vaccines but the companies are getting them ready in case we do. albert bourla, pfizer ceo

shep >> meg tirrell, thanks so much >>> dr. vin gupta, nbc news contributor, affiliate assistant professor at the university of washington dr. gupta, as always, thank you. for anybody about to get a vaccine shot, what should they know about these potential side effects, and is there a way to prepare, or do you just dive in? >> shep, good evening. there's no real way to prepare what i would say is we know that if you've had a previous significant allergic reaction to a vaccine of a different type, not for covid -- say the flu or another vaccine -- frankly, i counsel patients who have had food allergies that are significant or medication allergies, talk to your clinical provider they might be wise to ask you to see an allergist to make sure you're safe for the covid vaccine. what's a clear contraindication to the vaccine is if you've actually had a dose of vaccine and had severe anaphylactic reaction. if you're in line, what i'd also say is there's clear guidance from the cdc that after you've had your vaccine,, aches or low-grad

almost 100,000 signatures already on a change.org petition cnbc's meg tirrell has her story. >> i'm tryingcan't change. >> reporter: at the age of 51, lisa stockman got a shocking diagnosis. als, better known as lou gehrig's disease. >> as bad a diagnosis as als is, lisa's prognosis is even worse. >> reporter: she has a fast-moving form driven by a specific genetic mutation. but it initially appeared medicine might have an answer. biogen has a drug in clim trials specifically targeting that kind of disease lisa and her doctor requested compassionate use, a way to use experimental drugs when few other options. president trump championed the system signing in 018 a law known as right to try. >> thousands of terminally ill americans will finally have the help, the hope and the fighting chance that they will be cured. >> reporter: but for many that's been false hope. in lisa's case biogen has said no it's running a placebo-controlled trial to determine if the drug truly works and wrote in a letter to lisa that if it offered others the drug outside the trial, it, quote, could not in good faith

merck reported promising resulting from a study that tested its experimental covid pill cnbc's meg tirrellovers science and medicine for us. this could be a kind of tamiflu for covid, that is right >> merck's drug is among the most advanced of new treatments, oral, antiviral drugs, and there were earlier hints from a medical conference this weekend, that that medicine, as well as another from a company called atia may offer the possibipossibility of a simple pill for the disease. dr. fauci telling us what drugs like this have been able to do for other viral diseases. >> we need the same sort of thing for hiv and hepatitis c. we need an oral drug that potently can suppress the virus. i believe strongly that we will get there. the question is how quickly we'll get there. >> and it's taken longer to develop these medicines than it did for vaccines for covid or the antibody drugs authorized for high risk patients enrollment in trials has been slower than hoped, and experts note these drugs are complex, some that are farther along were originally developed for sars almost two decades ago and ot

meg tirrell is here with more on that front meg, good morning again. >> reporter: good morning, becky on its covid vaccine from its u.s. trial. this after monday putting out the interim results and being criticized by an oversight board for using what they said was outdated data. now we're seeing the updated information. it really didn't change that much 76% efficacy against symptomatic covid-19 now seen in this trial versus 79% we saw monday still reporting 100% efficacy against severe disease, although now there are more cases in the trial to support that finding. 190 total cases, 49 more than they reported on monday, eight severe cases up from five, guys. really these data not changing all that much and dr. has hashihashish zs h hashish zsha says it looks like a great vaccine but terrible communication. >> it's been baffling recently. >>> news alert on united airlines let's get to phil lebeau with details. phil >> reporter: wilf, we're seeing this from a number of airlines united out with an expansion of services this summer this case, it is going to be targeting vacationers in the

the united states, the company reports, its study turned up no serious side effects at all cnbc's meg tirrell covers science for us break it down for us, the data if you could. >> yeah, shep the data were better than many expected after some more mixed results from previous trials. now overall efficacy for the astrazeneca vaccine was 79% in preventing symptomatic covid-19, and 100% against severe disease and hospitalization. and importantly, no major safety concerns were identified the oversight board looked specifically for the risk of blood clots in the trial given concerns in europe and found none, although, many experts pointed out those are such rare events, they might not turn up even in a trial like this of more than 30,000 people. now, these were results that the company needed before it could file for u.s. clearance of the shot astrazeneca's u.s. president told us today they plan to submit their application to the fda in the first half of april, and they'd have 30 million doses ready immediately upon emergency use authorization. now, if it follows the same time line as for the three

college students the results could shape the future guidelines for all vaccinated americans cnbc's meg tirrell with the details of this new study. >> hey, frank, it's a study they're calling prevent covid u and aims to enroll people across the country using moderna's vaccine. why college students they live close together, interact more and have higher rates of i rates of infection, though relatively low rates of severe disease. the plan, vaccinate 6,000 volunteers immediately and another group of 6,000 four months later they'll all be asked to answer questions on an app and swab their noses every day and provide periodic blood samples the study is not just following those 12,000 people. additionally about 25,000 people will be identified as their close contacts and they too will be asked to provide samples. dr. fauci says this is how they aim to measure the vaccine's impact on transmission. >> the next five or so months, we'll be able to answer the very important question about whether vaccinated people get infected asymptomatically, and if they do, do they transmit the infection to others. >>

meg tirrell has more. >> almost 4 million doses of the j&j's vaccine this week after the cdc and fda gave their blessings. currently cdc advisers finishing up a two-day meeting this is the third veeck on the market it showed 72% efficacy, and 85% against severe disease worldwide. of course, this is a vaccine just one shot. it's fridge stable for three months, making it easier to store and distribute how much of this vaccine is actually going to be available we're hearing immediately, at least, it will be spotty j&j does expect 20 million to be shipped this month and 100 million by the end of june we show with j&j's ceo this morning. >> the nice part about our vaccine is when we're talking doses, that's actually the numbers of patients that will ultimately get a shot in their arm. we're absolutely committed and we won't stop until we make it happen >> now, guys, the messaging you are hearing from the government is get whatever shot you can when it becomes available. as people are making these comparisons among the vaccine, what's most important, they say is all three protect against s

crossing the 30-million case mark the path of the virus is concerning meg tirrell has more meg? are hearing that cases are risinging in certain parts of the country. now the 7-day average of new daily cases more than 57,000 up 6% from the week before and of course this is not happening across the country certain states seeing more spread than others this, of course, as president biden announced yesterday to expand the goal for the number of vaccinations being done in the first 100 days now to 200 million that's double. they say they have to stay on a pass of 2.5 million doses add menstered every day here and today they set a new record, 3 hadn't 4 million total shots administered so keeping that pace they hit that goal of 200 million in the first 100 days. there is some evidence emerging that the vaccines are taking effect and having a positive impact if you look at hospitalizations among people over 65 these are charts that you can see the orange line declining faster than the blue line, people under 65 and people of older ages are more vaccinated than people younger so this co

want to get straight over to meg tirrell who joins us with more meg. >> reporter: hey, andrew we understandt this week of the j&j vaccine after getting the blessing over the weekend of both the fda and the cdc. this of course is the third coronavirus vaccine to be available in the united states the first that only requires just one dose. now j&j had been ramping up the vaccine bringing on multiple partners to make it as available as possible. over time it will dramatically increase the availability of vaccines here in the u.s., but we understand that the availability will be a little bit spotty over the next couple of weeks j&j will be providing 4 million this week, none will ship next week we should be getting up to 20 million by the end of march and 100 million doses by the end of june because this is just one shot, that's enough for 100 million people in the first half of the year we're seeing shots live now preparing to ship that vaccine out to states where the states will be making allocations of this vaccine there are a lot of questions about how it will be used compared with the pfiz

meg tirrell with the latest. meg?new results of the eli lilly's cocktail of the two antibody drugs for covid shows that it can reduce the risk of hospitalizations and deaths by 87%. this is in the setting where this drug has emergency use authorization, and high risk patients recently diagnosed with this disease. now the eli lilly compound as well as one from regeneron with forms of antibodies on the market for covid. in the beginning, it was difficult for some patients to get access to these, and questions of how well they work against the variants, and so for answers to those questions we bring in the chief scientist for eli lilly, and dr. gravanski and we knew that the data was good behind the antibody drugs, and what does this data brin drug >> yes, meg, it was less than a year ago we talked about kicking off this program, and now a year later with the highest level of evidence for drug, and two randomized control drugs, and highly statistical significant on the key outcome measure here which is reducing hospitali

. >>> welcome back it has been one year sin the coronavirus outbreak bam a pandemic meg tirrell has as trying to keep pace with the new variants of the virus. hey, meg. >> there are few variants of concern that public health experts are following closely. of those, one known as b-1.351 poses the most dangerous we spoke with andrea carvy head of infectious disease research there who told us each time a new variant is reported their scientists calculate the risks it can pose. dr. fauci told us if updated vaccines are med they could be cleared for market with smaller studies. >> a bridging study where they can say a, it's safe, b, it induces an immune response that's correlated with protection, so you don't need a 30,000 person trial to show efficacy you could declare efficacy on the base i have a compare to have correlative immunity. >> reporter: it is not a given that we will need updated vaccines or boosters a vaccine scientist told us today he believes the vaccine's protection will last two to three years. but science and industry are making sure they are ready if we do >> i guess we

back on my peloton and pedal faster >>> but delivering that production into the arms of people, meg tirrellat still seems to me to be the bottleneck here talk us through it >> absolutely, tyler we have seen a number of shots being administered daily here climb now almost 2 million a day on average we heard from president biden yesterday, they are setting a new goalpost of having enough supply for every adult in the united states by the end of may. that as moved up from what he was say by the end of july crunching the numbers, it looks like we're about on pace with j&j, but including the partnership with merck and using the production act, they say the 100 million doses from j&j will be moved up by may than the end of june. though we don't have it cleared for kids, it's more than enough for the adults in the country. astrazeneca expecting results from the phase three trial within weeks we spoke with the head of biopharmaceutical on what supply they would have if they get eua. >> we're already producing at high speeds. we feel comfortable to have 50 million after the first month. after that,

major universities to require its students to have a vaccine before returning to campus in the fall meg tirrellers and others actually mandate this >> yeah, ali, it depends on who you ask. two lawyers we spoke with said yes. they can require covid vaccines in order to come to on-campus classes. >> to prevent having to close down again, it makes a lot of sense. i'll also add this isn't the first vaccine that universities have mandated. >> rutgers says it will add the vaccine to the list that also includes measles, mumpses and rubella. they may request xemplgss and it's not requiring fab cut and staff to get the vaccine, though it's strongly earn couraging it. that's because the positivity rate is much higher among students, they said. students said they were excited about what widepress vaccination could mean for the fall. >> it would be good that everyone will be vaccinated. definitely a lot safer i'm just more excited for the fall semester. >> hopefully sophomore year can be a real college experience. >> i'm ready to have more people out there and get to enjoy normal life again. >> there was b

to $1 million range as well >> thank you >>> we'll start with some of the big news out of pfizer meg tirrell >> so pfizer has been testing its covid-19 vaccine in ages down to 12 the first results out from that cohort of 12-year-olds to 15-year-olds shows strong efficacy and a well tolerated vaccine for kids in this trial of about 2,200 kids ages 12 to 15, they saw 100% efficacy. that was found with 18 cases in the placebo group and zero percent in the vaccine group not huge numbers they were looking to see how well this was tolerated among these kids who have such a strong immune response pfizer's ceo saying they plan to submit the data to the fda as a proposed amendment to their emergency use authorization and to other regulators around the world with the hopes of vaccinating this age group before the start of next school year pfizer has started moving into lower age groups as well with trials, dosing the first patients ages 5 to 11 last week and plan to start ages 2 to 5 next week. ultimately getting down to as low as age six months. guys >> they're moving aggressively here another thing

m meg tirrell is back and joins us with the details hi, meg. >> these were highly anticipated data thel, 79% efficacy overall in preventing symptomatic disease. they say 100% efficacy against severe disease and hospitalization. we learned this morning they had five cases of severe disease among people who got the placebo and none among people who got the vaccine. they saw no vaccine related safety concerns and appeared to be well tolerated. they specifically looked into the risk of blood clots given the concerns in europe, and said they did not see that. people note that is a rare event and you might not see that in a trial even of this size. we heard from the president of astrazeneca's u.s. business that they plan to file for an emergency use authorization in the first half of april and if this goes along the same lines of timing to an emergency use authorization if the fda gives the green light, about three weeks later we could see this on the u.s. market. at that point, though, we'll have a lot of other vaccines available as well. we asked dobber what role this could play in the u.s

first breaking news out of pfizer we have that, meg tirrell. >> reporter: jon, pfizer announcing a humanlinical trial of a bill for covid-19 the early stages phase one clinical trial but an oral anti-viral drug targeting this virus known as a protiase implicater, successful in treating hiv and hepatitis c and the kind of drug dr. fauci talked about we need for sars-cov-2 the chief scientific officer saying in a statement here "we've designed this drug called pfo71322, first sign of infection without require's that patient's hospitalization or being in critical care it's a pill. another inhibitor given by iv. the early stages of these drugs. the hope, showing positive results, move through clinical trials and could present a new option for treating covid-19 this the early start deirdre? >> thank you continue to track it for us. >>> mean fooimfooim -- meantime, microsoft in a deal to further bolster software and services side of its gaming business. where we start with "new york times" tech columnist, and kevin thanks for joining us. >> thanks for having me. good morning >> kevin, i've see

first, meg tirrell on the impact hi, meg. >> hey, shep though this is the third covid-19 vaccine to be rolled out in the u.s., state and local health departments are saying it will open up new possibilities for vaccinations. >> the fact that it offers us one dose and the fact that it has much easier logistical requirements, storage requirements, it can be stored in refrigerated temperatures, gives us an opportunity to reach some people in the state that we may not have been able to reach as easily with moderna and pfizer. >> oklahoma is targeting rural hospitals and people who are home bound, while washington state tells us it could provide a good option for the fishing industry where people live in congregant settings on ships advisers to the cdc cite e mobile or pop up clinics and primary care doctors offices that don't have freezer capacity so the j&j vaccine's ease of use enables more options for expanding vaccinations, but it's also being compared unfavorabl to the pfizer and moderna vaccines when it comes to efficacy it was 72% effective in the u.s. in preventing disease but 85 a

home, and it is a very different story overseas, particularly coming to astrazeneca's vaccine, and meg tirrell is joining with us the latest anda special guest on, that meg. >> brian, thank you so much. public health experts will tell us that the pandemic risk to us in the united states and everywhere is not gone until it is mitigated everywhere around the world. astrazeneca and oxford this week announcing they are shipping the first doses of the vaccine to low and mild income countries and for some of these, the first access of the vaccines they are getting this week to ghana, and coat cotedivoire. and some these are piling up of the doses as they say there are not enough data for the vaccines in older people, and so to join us to discuss this is dr. rube dobber and vice president of astrazeneca, and so, thank you for joining us. start with the report out of europe with the idea that there is not enough data to use the vaccine in older people, and how does astrazeneca look at the approach >> thank you for having us on the show. and first of all, it is important to look at the regulators appro

going to start with more trouble on the vaccine front the role of astrazeneca's covid-19 front meg tirrell week for astrazeneca. monday we got the efficacy results showing 79% protection against symptomatic disease but then just hours later the data safety monitoring board, the oversight board warned the data were outdated and we heard they could have been misleading in terms of efficacy. the company now has released updated results that really, guys, haven't changed much now they're saying the efficacy was 76% against symptomatic covid-19, in terms of severe disease which many experts say is the most important thing for a vaccine. still 100% efficacy. the estimate for people over 65 went up to 85% efficacy from 80%. there were more cases now in this updated look for them to analyze. 190 now as of this data cut. eight severe cases so strengthening that finding up from 141 overall cases as of the last time. guys, the head of research for astrazeneca saying this primary analysis is consistent with the previously released interim analysis quote, we look forward to firing our regulatory submis

let's bring in meg tirrell to discuss the key takeaways from that and of course as a number of peopleoric nearly unprecedented collaboration between these two companies showing some fruits. >> yes, a lot of comparisons to world war ii you heard the president make it there between the car companies, the aviation companies, and now the pharmaceutical companies working together here. that question about surplus is really interesting because even already with the doses that they had purchased we'll have enough for 400 million americans by the end of july. that's more than we have people in this country. now they are announcing an additional hundred million dose purchase from johnson & johnson. that is enough for 500 million people the implication is and president biden got at this a little bit if there are new challenges where we need a new vaccination effort it sounds like they are getting prepared for potentially needing booster shots or potentially updating the vaccines against variants and that is leaving out the astrazeneca vaccine, novavax, vaccine, all of which will have data from

meg tirrell has more on the current state of the vaccine situation. meg? >> wilf, on the novavax news that came out yesterday after the close, really what it was was final efficacy data on a trial where we had seen the interim results at the end of january. the stock up 7.6% now. it was up as much as 20% earlier today. what we learned if there were more cases in the trial of severe disease, they were all in the placebo arm. among those who received the vaccine making it a 100 efficacy in south africa, 55% among people who were hiv negative and 86% against the b.1.17 variant. that's novavax we also have taken a look at the three vaccines that are here on the market in the united states trying to get a sense of whether there was a sort of brand preference that people might have remember, the message from public health officials is take which ever vaccine you can get first. but we asked folks through a global data and survey firm if they had the choice, which would they choose? more than a quarter of people said they really don't have any preference more than

mike santoli tracking the action, meg tirrell with the vaccine action mike, start us off as we approach one year since the covid bottom. >> tomorrow the anniversary, sara today the index level looks like it's very much on trend and hitting 3950 it's been at or above this level five of the last seven days not including today, so clearly it's spending some time up in this higher range now today there are more stocks down than up this is one of those days yields are backing off. it's flattering the s&p because the mega caps are leading and that's usually been the toggle we've been on for a while now. so, again, with the index level, as long as it's above the mid-3800, it seems like this trend is intact, even if it's had a hard time making a real run up toward that 4,000 level take a look at this comparison of the total return in the 10-year treasury this time around, the last several months, compared to 2013, that was the year of the taper tantrum. this is from renaissance macro obviously very much point-to-point a similar time move, similar type losses, yields going up. back then from 1.6

so j&j is the only one-dose shot >> meg tirrell reporting. >>> ev street.hy wood getting more bullish on her tesla bet plus volkswagen announcing a crossover utility vehicle. those details ahead. stay with us ♪ mom and dad left costa rica, 1971. and in 1990, they opened lrazu. when the pandemic hit, pickup and delivery was still viable. that kept us afloat. keeping our diners informed on google was so important. the support from our customers, it honestly kept us going. i will always be grateful for that. ♪ we see breakthrough medicines getting to patients in record time. at emerson, our automation software is empowering pharmaceutical companies to accelerate their production of critical vaccinations for the world. emerson. consider it solved. - [narrator] grubhub perks give you deals on all the food that makes you boogie. of critical vaccinations for the world. (upbeat music) get the food you love with perks from- - [crowd] grubhub. >>> welcome back kathy wood making a dramatic call on tesla, now expecting tesla stock price to reach $3,000 by 2025 you see

meg tirrell joins me. >> if other countries don't get access to the vaccine, it could prolong the pandemic. here in the u.s., we should have enough vaccine for every american adult by the the end of may which is 500 million doses from pfizer, moderna and johnson & johnson, and to put it in comparison, the covax organization that is helping to get vaccines to lower and mid-income vaccines will have half that many doses to distribute from astrazeneca to 104 countries in that time period. according to duke university, about 16% of the world's countries have acquired half of the world's vaccines versus the lower and middle, and that is a major difference here. we are hearing from the experts warning that the variants pose more of a risk here, because as they continue to circulate around the globe if those populations are not vaccinated the risk of new variants spreading to new countries getting vaccinated gets higher, and economist analyst says that some countries may not have the majority of the population having access to 20203, and so the risk could continue to persist. one suggestion is th

connecticut detecting at least 45 cases of a brand new variant first discovered in new york cnbc's meg tirrell, who do we know >> new york officials are quite concerned about b1526. it accounted for 45% of all samples sequenced from the city. the health commissioner telling us that variant along with b.1.1.7 first identified in the uk are likely keeping cases higher in new york >> as the city's doctor i'd much rather see cases plunging rather than plateauing and part of the reason for the plateau that we're seeing i believe is those more infectious variants >> scientists suspect the variant is more transmissible than older strains although not clear by how much. it's been found in more than 30 states but it's most prevalent in the northeast the cdc characterized it as a variant of interest, not yet one of concern, although director dr. rochelle walensky told us today that's under review. >> early data suggests increasei transmissibility of b.1.5.2.6 not as transmissible at b.1.1.7. >> right now 1.1.7 seems to be spreading faster across the country and really becoming a more predominant strain

. >> meg tirrell, thank you so much. >>> jury selection delayed until at least tomorrow in the murder trial of derek chauvin, the man who was a cop when he allegedly killed george floyd in minneapolis. prosecutors asked for the delay. they're trying to bring back a third-degree murder charge against chauvin that the judge tossed out that's chauvin on the right there with the black mask. video of chauvin kneeling on george floyd's neck for nearly nine minutes sparked outrage last summer and demands for police reform across the nation. earlier today on msnbc, george floyd's brother said the evidence against chauvin is clear. >> you've seen the video, my brother was tortured to death while he had a smirk on his face, and if you can't get justice in america for that, what can you get justice for. >> protesters marched outside the courthouse today where security has been intense with national guard troops on the ground here's nbc's jay gray. >> prosecute the police. >> reporter: as crowds stand up outside the hennepin county courthouse, inside the courtroom, a judge is told potential membe

fatigue and muscle pain but the experts say they typically go away within a day or two here's cnbc's meg tirrell. >> reporter: this doctor says covid-19 vaccine appointments were staggered among staff because the second dose can pack a temporary punch. >> we knew people could miss a day or two of work. >> reporter: as the vaccines roll out across the country, many americans are having the same experience. >> for me it was the body aches that were the most severe. i felt like i'd been hit by a truck for six hours. >> i could feel every joint and muscle of my body just really began to ache. i felt very sore temperature-wise, i had wild fluctuations. >> reporter: carney lewis and eric ganard got the pfizer and moderna vaccines respectively. it's not just the second dose that come with elections alex, 24-year-old child care worker, received the one-shot j&j vaccine. >> the 12th hour hit and i got a horrible fever i felt the skin tingles you get before it sets in. >> reporter: she'd scheduled her vaccine appointment on a sunday thinking she'd have pfizer or moderna and feel fine to go to work after t

vaccine clinical trial and meg tirrell has been waiting with these numbers. they are good, meg they are not in the 90s. all of the vaccines. give me any of them. twice. six times. >> reporter: exactly, joe. this would be twice. a two-shot dose from the vaccine. 32,000 people in the trial headline number. 79% efficacy against systemic disease. for people over 65, this was an important group because there was questions of efficacy. 80% efficacy for people 65% and older. they looked at whether there was a risk of blood clots. there were concerns in europe. there were no safety concerns. including clotting this was run in u.s. and chile and peru they are going to continue to a analyze data they gave the shots four weeks apart. they saw in previous trials when they spaced the doses farther apart, the efficacy number went up it will be interesting to see what the strategy is with the fda and what the dosing strategy turns out to be. 79% efficacy higher than many people expected for the results given what we have seen around the world so far guys, this is a vaccine t